Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in …

encephalopathy
carcinoma
varicose veins
fibrosis
pivka-ii
  • 0 views
  • 19 Feb, 2024
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

hair thinning
carcinoma
renal function test
vitiligo
type 1 diabetes mellitus
  • 0 views
  • 19 Feb, 2024
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide and is a major cause of cirrhosis and liver cancer in Western countries. Because of its close association with obesity and diabetes, most patients are seen by primary care physicians and endocrinologists rather than hepatologists.

fatty liver
hepatic fibrosis
cirrhosis
cancer
liver cancer
  • 0 views
  • 19 Feb, 2024
Irreversible Electroporation of Unresectable Liver Tumors

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

biliary tract cancer
hepatoma
metastasis
cancer
irreversible electroporation
  • 0 views
  • 19 Feb, 2024
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

Hepatic metastases are common in solid cancers (up to 30% of patients with colorectal cancer and up to 50% of patients during their follow-up). The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and …

liver diseases
cancer
liver cancer
stereotactic radiation therapy
hepatitis
  • 0 views
  • 19 Feb, 2024
Neo-TACE-HAIC for BCLC B Stage HCC (Neoconcept)

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although BCLC (Barcelona clinical liver cancer) system recommend to transarterial chemoembolization (TACE) for BCLC B stage patients, increasing studies suggested that hepatic resection provided survival benefit for those patients.

carcinoma
oxaliplatin
fluorouracil
cancer
liver cancer
  • 0 views
  • 19 Feb, 2024
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable.

encephalopathy
carcinoma
liver mri
cancer
cirrhosis
  • 0 views
  • 19 Feb, 2024
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma

This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.

carcinoma
radiofrequency ablation
recurrent hepatocellular carcinoma
hepatocellular carcinoma
stereotactic body radiation therapy
  • 0 views
  • 19 Feb, 2024
Preliminary Antitumor Activity Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

cholangiocarcinoma
carcinoma
unresectable hepatocellular carcinoma
cancer
liver cancer
  • 0 views
  • 19 Feb, 2024
Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of small esophageal varices with no risky signs and shortening endoscopic follow-up time intervals to reduce the risk of variceal hemorrhage.Researchers will assess the …

  • 0 views
  • 09 May, 2025